China is systematically building healthcare technology dominance across Asia-Pacific by positioning genomics companies as essential infrastructure partners for developing economies. The HGP2 Rare Disease Alliance was launched on May 10 in Kuala Lumpur, uniting 10 countries under a shared framework.

BGI Genomics, the Chinese company leading this initiative, is deploying high-throughput sequencing systems and AI-powered diagnostic platforms throughout Southeast Asia and South Asia.

China establishes institutional dependencies through its affordable solutions and workforce development programmes and complete technical assistance which extend beyond individual technology agreements.

BGI is establishing national-level rare disease diagnosis centres, starting with Thailand's Ministry of Public Health. The company's iGeneT Pro platform automates genetic analysis in minutes, a capability that previously required years.

For lower- and middle-income countries, this technology transforms diagnostic capacity overnight, but it also creates reliance on Chinese expertise and systems.

The strategic advantage lies in embedding infrastructure. Once countries deploy BGI systems, retrain clinical staff, and integrate platforms into health ministries, switching to competitors becomes operationally expensive and politically complicated. This is how technology becomes geopolitical leverage.

The training programme for regional geneticists and clinicians at China's Interpretation of Genetic Diseases Training Workshop focuses on BGI's proprietary systems. The partnership framework between organisations establishes ethical standards and accessibility requirements while it builds technical standards that match Chinese technological standards.

The Deputy Director General of Health in Malaysia described the project as achieving precision health through the combination of genomics, artificial intelligence, advanced technology and strong policy frameworks.